...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: What's going on with the Phase 2 ZEN-3694 mCRPC trial?

All this drip PP financing  from across the Pond in germany has me wondering if someone in the tight ownership/management  circle of Ingelheim boehringer has an interest in a buyout of both RVX and Zenith if results of BETONMACE is really good,   There was a connection of Peter Johann on RVX BOD who was conncected to Ingelheim Boehringer at some point in the past,  Just seems intersting the latest  PP is from Germany,... At least the lights can still be paid for now.... LOL

Share
New Message
Please login to post a reply